Congress Materials - United European Gastroenterology (UEGW 2025)
2025 United European Gastroenterology | Oct 4-7 | Berlin, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Benefit-Risk of guselkumab compared to placebo in the treatment of moderately to severely active ulcerative colitis
Ellen Janssen, Thomas Baker, Jacqueline Yee, Hewei Li, Ye Miao, Matthew Germinaro
Comparative Efficacy of Guselkumab vs. Risankizumab in Induction Phase for moderate to severe Crohn's Disease: An Anchored MAIC Analysis
Suzy van Sanden , Marco Trevisan , Alina Strobl, Daniel Wirth
Comparison of pharmacodynamic serum IL-22 and mechanistic tissue molecular changes between guselkumab subcutaneous and intravenous induction dosing in moderately to severely active Crohn’s disease: Post-hoc analysis of the GRAVITI and GALAXI Phase 3 studies
Klebea Sohn, Dylan Richards, Ruchi Patel, Amy Hart, Christopher Sisk, Mobolaji Olurinde, Natalie A. Terry, Bradford McRae, Walter Reinisch, Flavio Steinwurz, Remo Panaccione, Geert D’Haens, Patrick Branigan
Earlier Use of Guselkumab Is Projected to Yield Long-Term Sustained Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Mariya Dimova, Mi Jun Keng, Dominik Naessens, Sumesh Kachroo, Shashi Adsul, Mario Gomez, Elise Wu
Effect of Guselkumab Subcutaneous Induction and Maintenance on Bowel Urgency and Abdominal Pain as Measured by the UC-PRO/SS in Participants With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ASTRO Study
Silvio Danese, Laurent Peyrin-Biroulet, Millie Long, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Mary Kavalam, Chenglong Han, Silke Jorgens, Lingjing Jiang, Hongyan Zhang, Tadakazu Hisamatsu, David T. Rubin, Jessica R. Allegretti
Effects of Subcutaneous Guselkumab Induction and Maintenance on Histologic Outcomes in Patients with Moderately to Severely Active Crohn’s Disease in GRAVITI, a Phase 3 Double-blind, Placebo-controlled, Treat-through Study
Geert R. D’Haens, Ailsa Hart, Remo Panaccione, Flavio Steinwurz, Qian Cao, Mobolaji Olurinde, Leonardo Salese, Patrick Branigan, Wilbert van Duijnhoven, Natalie A. Terry, Silvio Danese, Tadakazu Hisamatsu, Bruce E. Sands
Efficacy and safety of subcutaneous guselkumab induction and maintenance therapy in patients with ulcerative colitis: Results through Week 48 from the Phase 3 ASTRO study
Jessica R. Allegretti, Laurent Peyrin-Biroulet, Millie Long, Matthew Germinaro, Thomas Baker, Mary Kavalam, Yelina Alvarez, Karen Hertzog, Silke Jörgens, Hongyan Zhang, Lingjing Jiang, Tadakazu Hisamatsu, David T. Rubin, Silvio Danese
Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients with Moderately to Severely Active Crohn’s Disease and Inadequate Response to Ustekinumab: Results From GALAXI 1, 2, & 3 Long-term Extension
Anita Afzali, Douglas Wolf, Rupert Leong, Rian Van Rampelbergh, Wilbert van Duijnhoven, Christopher Busse, Tadakazu Hisamatsu, Julián Panés
Intravenous and Subcutaneous Guselkumab Induction Therapy Are Both Efficacious in Crohn’s Disease Patients With High Baseline Disease Severity: Results at Week 12 From the Phase 3 GALAXI and GRAVITI Studies
Bruce E. Sands, Tadakazu Hisamatsu, Anita Afzali, Natalie A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Jacqueline Yee, Wilbert van Duijnhoven, Ailsa Hart, Silvio Danese, Remo Panaccione
Efficacy of Guselkumab for Small-Bowel Lesions Using Balloon Assisted Enteroscopy: A Phase 3, Open-label, Multicenter Study
Teppei Omori, Kazuo Ohtsuka, Kenji Watanabe, Taku Kobayashi, Naoki Hosoe, Motohiro Esaki, Tomoki Matsuda, Takehiko Sakamoto, Koji Masuda, Madoka Chinen, Hiroshi Horio, Shinichi Yoshigoe, Tadakazu Hisamatsu
Efficacy of Guselkumab in Moderately to Severely Active Ulcerative Colitis by Extent of Disease and Inflammatory Burden: Subgroup Analysis of the Phase 3 QUASAR Maintenance Study
Jessica R. Allegretti, Tadakazu Hisamatsu, Brian Bressler, Laurent Peyrin-Biroulet, Matthew Germinaro, Shadi Yarandi, Nicole Shipitofsky, Ye Miao, Bruce E. Sands, David T. Rubin, Axel Dignass
Endoscopic Patient Clustering to Investigate Differential Treatment Effects of Guselkumab and Ustekinumab in Crohn’s Disease: Post hoc Analysis of GALAXI and GRAVITI Trials
Dylan Richards, Loqmane Seridi, Klebea Sohn, Brad Mcrae, Nat Terry, Marion Vetter, Daniel Cua, Patrick Branigan, Walter Reinisch, Raja Atreya
Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn’s disease in the GALAXI Phase 3 studies
Anita Afzali, Tadakazu Hisamatsu, David T. Rubin, Nat A. Terry, Rian Van Rampelbergh, Jacqueline Yee, Kitty Yuen Yi Wan, Zijiang Yang, Walter Reinisch, Bruce E. Sands, Silvio Danese, Remo Panaccione
Guselkumab Pharmacokinetics and Exposure-response Relationships Are Consistent Following Intravenous Versus Subcutaneous Induction in Participants with Crohn’s Disease
Geert R. D’Haens, Omoniyi J. Adedokun, Tae Eun Yang, Bruce E. Sands, Silvio Danese, Nat A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Marion L. Vetter, Tadakazu Hisamatsu, Remo Panaccione
Guselkumab versus risankizumab as maintenance treatment for moderately to severely active ulcerative colitis: Network meta-analyses of clinical and endoscopic outcomes
Elise Wu, Dominik Naessens, Mario Gomez, Ashley Bonner, Maxwell Jones
Icotrokinra, a targeted oral peptide that selectively blocks IL-23 receptor activation, in moderately to severely active ulcerative colitis: Week 12 results from the Phase 2b, randomized, double-blind, placebo-controlled, treat-through, dose-ranging ANTHEM-UC trial
Maria T. Abreu, Britta Siegmund, Lindsey Surace, Ngozi Erondu, Minhu Chen, Karen Chachu, Edouard Louis, Katsuyoshi Matsuoka, Jimmy Limdi, Edmund Arthur, Nicole Houck, Mary Ellen Frustaci, Bin Zou, Grazyna Rydzewska, Edward V. Loftus, Jr., Vipul Jairath
Impact of subcutaneous guselkumab therapy on molecular inflammation in patients with ulcerative colitis: results from phase 3 ASTRO study
Swati Venkat, Sunandini Sridhar, Barbara Shaikh, Klebea Sohn, Jared Liu, Christopher Sisk, Bradford McRae, Yelina Alvarez, Tom Baker, Matthew Germinaro, Jessica R. Allegretti, Millie Long, David T. Rubin, Laurent Peyrin-Biroulet, Amy Hart, Patrick Branigan
Maintenance of Endoscopic and Histologic Efficacy with Guselkumab for Ulcerative Colitis at Week 92 of the QUASAR Long-Term Extension Study
Tadakazu Hisamatsu, Julián Panés, Fernando Magro, Gary R. Lichtenstein, Jessica R. Allegretti, Brian Bressler, Waqqas Afif, Mark A. Samaan, Byong Duk Ye, Shadi Yarandi, Matthew Germinaro, Nicole Shipitofsky, Dwiti Pandya, Ye Miao, Hongyan Zhang, Axel Dignass, David T. Rubin, Bruce E. Sands
Molecular differentiation of guselkumab and ustekinumab in moderately to severely active Crohn’s disease: Post hoc analysis of the GALAXI 2 and 3 phase 3 studies
Dylan Richards, Klebea Sohn, Martha Zeeman, Ruchi Patel, Bradford McRae, Nat Terry, Marion Vetter, Walter Reinisch, Daniel Cua, and Patrick Branigan
Therapeutic and hospitalisation outcomes after first line anti-TNF in inflammatory bowel disease: EPITHERA study
J. Kirchgesner, L. Peyrin-Biroulet, L. Gautier, K. Sosnowiez, S. Chaalal, L. Clevy, H. Omichessan, V. Cohignac, P. Rabiéga, G.Bizouard, T. Nishikawa, A. Huguet, L. Vuitton
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
